Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

Kathrin Strasser-Weippl, Nora Horick, Ian E. Smith, Joyce O'Shaughnessy, Bent Ejlertsen, Frances Boyle, Aman U. Buzdar, Pierre Fumoleau, William Gradishar, Miguel Martin, Beverly Moy, Martine Piccart-Gebhart, Kathleen I. Pritchard, Deborah Lindquist, Erica Rappold, Dianne M. Finkelstein, Paul E. Goss*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Introduction: Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described. Methods: Using data from 1,260 patients randomized to placebo in the adjuvant TEACH trial, we report 10-year annual hazards of recurrence in HER2+ patients not treated with anti-HER2 therapy. Results: Disease-free survival (DFS) was 75% after 5 and 61% after 10years, respectively. Patients with HER2+hormone receptor-positive (HR+ (hormone receptor-positive); ER+ (estrogen receptor-positive) or PR+ (progesterone receptor-positive)) disease had a significantly better DFS than patients with HER2+HR- (ER-/PR-) disease (hazard ratio 0.72, P=0.02). This difference was explainable by a significantly higher hazard of recurrence in years 1 to 5 in HER2+HR- compared to HER2+HR+ patients, with a mean risk of recurrence of 9%/year for HR- versus 5%/year in HR+ patients (hazard ratio 0.59, P=0.002 for years 1 to 5). The high early risk of recurrence of HER2+HR- patients declined sharply over time, so that it was similar to that seen in HER2+HR+ patients in years 6 to 10 (hazard ratio 0.97, P=0.92 for years 6 to 10). Conclusions: Our results show that outcomes in HER2+ patients with early BC not receiving anti-HER2 therapy strongly depend on HR expression. The very high early risk of relapse seen in HER2+HR- patients is particularly relevant in health care settings with limited access to adjuvant anti-HER2 treatment. The event rates shown for subpopulations of HER2+ BC patients suggest that in resource-constrained environments patients with HER2+HR- early BC should be prioritized for consideration of adjuvant anti-HER2 therapy.

Original languageEnglish (US)
Article number56
JournalBreast Cancer Research
Volume17
Issue number1
DOIs
StatePublished - Apr 16 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy'. Together they form a unique fingerprint.

Cite this